Literature DB >> 6094781

Thirty years of experience with pediatric primary malignant liver tumors.

M Giacomantonio, S H Ein, K Mancer, C A Stephens.   

Abstract

Since 1950, 48 infants and children from 10 weeks to 16 years of age presented with primary hepatic malignancy. Signs and symptoms ranged from asymptomatic to those of malignant disease. All patients had a palpable abdominal mass. Jaundice was seen in five patients, four of whom had preexisting cirrhosis. Three male children had evidence of precocious puberty. Whereas liver function tests were usually normal, alpha-fetoprotein levels, when elevated, proved useful diagnostically and as a tumor marker in follow-up. Hepatic angiography and computed tomography (CT) scans have provided the most valuable preoperative assessment of hepatic architecture. Sixteen infants and children underwent resection for cure. Eleven of these patients are alive and disease free 6 months to 23 years later. Six additional patients had incomplete resection with subsequent radiotherapy and/or chemotherapy; only one such patient is disease-free past 3 years. Twenty-six tumors could only be biopsied; most of these patients died within 12 months regardless of what treatment they received. The histology was hepatoblastoma in 39 patients, hepatocellular carcinoma in 4, fibrolamellar carcinoma in 4, and malignant mesenchymal tumor (mesenchymoma) in 1. The patients with hepatocellular carcinoma and mesenchymoma all died. Three of four patients with fibrolamellar carcinoma are alive and disease-free following resection up to 3 years; this histology seems favorable. The other survivors had hepatoblastoma. The role of adjunctive chemotherapy and/or radiotherapy has not yet been determined.

Entities:  

Mesh:

Year:  1984        PMID: 6094781     DOI: 10.1016/s0022-3468(84)80095-0

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  10 in total

1.  Hepatic lobectomies in children: experience of a center in the light of changing management of malignant liver tumors.

Authors:  Saniye Ekinci; Ibrahim Karnak; F Cahit Tanyel; M Emin Senocak; Tezer Kutluk; Münevver Büyükpamukçu; Nebil Büyükpamukçu
Journal:  Pediatr Surg Int       Date:  2006-01-03       Impact factor: 1.827

2.  Haemangioendothelioma in a preterm infant associated with highly elevated alpha-fetoprotein.

Authors:  T Lehrnbecher; G Frauendienst-Egger; L Schrod; A Marx; D Harms; H B von Stockhausen
Journal:  Eur J Pediatr       Date:  1996-05       Impact factor: 3.183

3.  Midterm results with hepatectomy after preoperative chemotherapy in hepatoblastoma.

Authors:  Minu Bajpai; K Pal; S Agarwala; Tulika Seth; Arun K Gupta
Journal:  Pediatr Surg Int       Date:  2005-04-19       Impact factor: 1.827

4.  Undifferentiated embryonal sarcoma of the liver: US and CT findings.

Authors:  W K Moon; W S Kim; I O Kim; K M Yeon; I K Yu; B I Choi; M C Han
Journal:  Pediatr Radiol       Date:  1994

5.  Primary malignant liver tumors in childhood: assessment of resectability with high-field MR and comparison with CT.

Authors:  J P Finn; M A Hall-Craggs; C Dicks-Mireaux; L Spitz; E R Howard; J Pritchard; G M Vergani
Journal:  Pediatr Radiol       Date:  1990

6.  Resection, including transplantation, for hepatoblastoma and hepatocellular carcinoma: impact on survival.

Authors:  E P Tagge; D U Tagge; J Reyes; A Tzakis; S Iwatsuki; T E Starzl; E S Wiener
Journal:  J Pediatr Surg       Date:  1992-03       Impact factor: 2.545

Review 7.  Conversion of unresectable to resectable hepatoblastoma and long-term follow-up study.

Authors:  M Reynolds
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

8.  [Surgical therapy of hepatoblastoma in childhood].

Authors:  D von Schweinitz; H Hecker; D Bürger; H Mildenberger
Journal:  Langenbecks Arch Chir       Date:  1995

9.  A rare cause of precocious puberty: hepatoblastoma.

Authors:  Erdal Eren; Metin Demirkaya; Esra D Papatya Çakır; Betül Sevinir; Halil Sağlam; Ömer Tarım
Journal:  J Clin Res Pediatr Endocrinol       Date:  2009-11-07

10.  Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors.

Authors:  Michael L Megison; Lauren A Gillory; Jerry E Stewart; Hugh C Nabers; Elizabeth Mroczek-Musulman; Alicia M Waters; Jennifer M Coleman; Virginia Kelly; James M Markert; G Yancey Gillespie; Gregory K Friedman; Elizabeth A Beierle
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.